Title: Double Dissociation of Nicotinic α7 and α4/β2 Sub-receptor Agonists for Enhancing Learning and Attentional Filtering of Distraction

Authors: Maryzeh Azimi¹, Mariann Oemisch¹,² and Thilo Womelsdorf¹,³

Affiliations: ¹Department of Biology, Centre for Vision Research, York University, Toronto, Ontario M6J 1P3, Canada; ²Department of Neuroscience, Yale University School of Medicine, New Haven, CT 06510, ³Vanderbilt University, Department of Psychology, PMB 407817, 2301, Vanderbilt Place, Nashville, TN 37240-7817

Running Title: Nicotinic sub-receptor specific modulation of learning and attention

Classification: Biological Sciences; Neuroscience

Corresponding Author: Dr. Thilo Womelsdorf, Vanderbilt University, Department of Psychology, PMB 407817, 2301 Vanderbilt Place, Nashville, TN 37240-7817; thilo.womelsdorf@vanderbilt.edu, TEL: +1 (574) 327-0486
Abstract
Nicotinic acetylcholine receptors (nAChR) modulate attention, memory, and higher executive functioning, but it has remained unclear whether nAChR sub-receptors tap into different neural mechanisms of these functions. We therefore set out to contrast the contributions of selective alpha-7 nAChR and alpha-4/beta-2 nAChR agonists in mediating value learning and attentional filtering of distractors in the nonhuman primate. We found that the alpha-7 nAChR agonist PHA-543613 selectively enhanced the learning speed of feature values but did not modulate how salient distracting information was filtered from ongoing choice processes. In contrast, the selective alpha-4/beta-2 nAChR agonist ABT-089 did not affect learning speed but reduced distractibility. This double dissociation was dose-dependent and evident in the absence of systematic changes in overall performance, reward intake, motivation to perform the task, perseveration tendencies, or reaction times. These results suggest nicotinic sub-receptor-specific mechanisms consistent with (1) alpha-4/beta-2 nAChR specific amplification of cholinergic transients in prefrontal cortex linked to enhanced cue detection in light of interferences, and (2) alpha-7 nAChR specific activation prolonging cholinergic transients, which could facilitate subjects to follow-through with newly established attentional strategies when outcome contingencies change. These insights will be critical for developing function-specific drugs alleviating attention and learning deficits in neuro-psychiatric diseases.

Introduction
Nicotinic acetylcholinergic receptors (nAChR’s) have long been implicated to modulate attention and learning (Deutsch JA 1971; Muir JL et al. 1992), and are primary targets for developing drug treatments for reinstating attention and flexibility to adjust behavior in schizophrenia, attention deficit hyperactivity disorder (ADHD) and Alzheimer’s disease (Wilens TE et al. 1999; Wallace TL, TM Ballard, et al. 2011; Ballinger EC et al. 2016). These effects are mediated by the prefrontal cortex whose innervation from basal forebrain cholinergic neurons is essential for successful reversal learning (Roberts AC et al. 1990; Wallace TL and D Bertrand 2013), and whose cholinergic concentration levels predict successful attentional detection of relevant visual cues (St Peters M et al. 2011; Howe WM et al. 2013). These insights into the cholinergic contribution to successful attention and learning raises the long-standing question whether these functional contributions can be dissociated, or else, might reflect the same underlying processes (Sarter M et al. 2003).
Evidence from a variety of sources suggests that the cholinergic influence on attention and learning functions might be mediated differentially by the α7 and the α4β2 nAChR sub-receptor systems (Sarter M et al. 2016; Thiele A and MA Bellgrove 2018). Both sub-receptors are expressed in prefrontal cortex and act pre-synaptically as autoreceptors or heteroreceptors to regulate the release of glutamate, GABA, dopamine and other neurotransmitters (Gotti C et al. 2006; Livingstone PD and S Wonnacott 2009; Bortz DM et al. 2013). However, subtle differences exist in their permeability of calcium and associated role in plasticity (stronger for α7), and in the amplification potential of glutamate signaling (stronger but shorter lasting for α4β2) (Albuquerque EX et al. 2009; Parikh V et al. 2010; Tanner JA et al. 2015). Moreover, prefrontal α7 and α4β2 receptors show a layer-specific expression profile with stronger α4β2 expression in thalamic recipient layer VI and α7 more prominent expression in layer V, which is rich in striatal projection neurons (Poorthuis RB et al. 2013). These differences in layer-specific action, calcium-mediated plasticity, and control of glutamate excitability make it possible that each sub-receptor plays separable circuit roles for attention and learning functions of the prefrontal cortex. To discern dissociable circuit roles, it is essential to establish a task paradigm and animal model showing sub-receptor specific sensitivity to attention and learning functions.

Task paradigms that simultaneously vary attentional demands and are sensitive to learning processes are sparse, which constitutes a bottleneck for advancing a mechanistic understanding of sub-receptor specific functions (Sarter M et al. 2003; Romberg C et al. 2013). For instance, in NHP studies, investigation of attentional processes in the context of nicotinergic experiments have been largely limited to testing distracting stimuli in working memory tasks (surveyed in Table S1, S2). To address this, we selected two sub-receptor agonists and tested them on a feature-based attention reversal learning paradigm in nonhuman primates (NHP’s) (Figure 1). The task distinguished feature-based covert attention from spatial response biases, varied the demands of attentional filtering of distractors, and quantified reversal learning flexibility. We conjectured that such a combined learning and attention paradigm is needed to clarify open questions about sub-receptor specific functions. In particular, an exhaustive literature survey of attention effects of fourteen studies applying systemically α7 agonists (Table S1) (Briggs CA et al. 1997; Hahn B et al. 2003; Buccafusco JJ et al. 2007; Buccafusco JJ and AV Terry, Jr. 2009; Rezvani AH et al. 2009; Wallace TL, PM Callahan, et al. 2011; McLean SL et al. 2012; Gould RW et al. 2013; Yang Y et al. 2013; Young JW et al. 2013; Jones KM et al. 2014; Kolisnyk B et al. 2015; Wood C et al.
Nicotinic sub-receptor specific modulation of learning and attention

2016; Wadenberg MG et al. 2017), and thirteen studies using α4β2 agonists (Table S2) (Buccafusco JJ et al. 1995; Decker MW et al. 1997; Prendergast MA, AV Terry, Jr., et al. 1998; Schneider JS et al. 1999; Schneider JS et al. 2003; Decamp E and JS Schneider 2006; Buccafusco JJ et al. 2007; Howe WM et al. 2010; Gould RW et al. 2013; Paolone G et al. 2013; Kolisnyk B et al. 2015; Terry AV, Jr. et al. 2016; Wood C et al. 2016) failed to reveal sub-receptor specific contributions to working memory and distractor filtering functions in the NHP animal model.

A similarly inconclusive pattern of results exists for set shifting and reversal learning tasks. Studies in rodents indicate that attentional set shifting and behavioral flexibility is closely associated with α7-specific signaling across five independent studies amplifying α7 sub-receptor activation with different systemic agonists (McLean SL et al. 2011; Wallace TL, PM Callahan, et al. 2011; McLean SL et al. 2012; Jones KM et al. 2014; Wood C et al. 2016; Wadenberg MG et al. 2017) (Table 1 and Table S1). However, in the one rodent study that compared a β agonist to an α7 agonist, similar set-shifting behavioral benefits were found with both sub-receptor specific types (Wood C et al. 2016). This result resonates with findings in the NHP where a study with mPTP-impaired NHPs reported that α4β2 agonist action was sufficient to normalize spatial reversal learning performance (Decamp E and JS Schneider 2006) in that both studies showed beneficial effects of selective agonists on a task component involving reversal of feature values. However, in conflict to these studies one study reported slower object reversal learning in NHP’s with a selective α7 agonist applied at a dose at which it improved delayed match-to-sample performance in the same monkeys (Gould RW et al. 2013), suggesting that α7 agonists can have negative influences on reversal learning at doses that working memory performance would benefit from.

In the context of the described result patterns, we aimed to establish for the NHP an attention and learning paradigm and identifies independently for an alpha7 and an α4β2 agonist the dose with likely beneficial behavioral effects. We report that α7 agonists were associated with faster reversal learning, that α4β2 agonists were associated with enhanced performance when distractor filtering was most demanding, and that neither sub-receptor system affected motor, reward, or overall performance components of the task.

Materials and Methods
Data was collected from a 9 and a 7-year-old adult male rhesus monkey (Macaca mulatta) following procedures described in (Hassani SA et al. 2017). All animal care and experimental protocols were approved by the York University Council on Animal Care and were in accordance with the Canadian Council on Animal Care guidelines.

**Behavioral Procedures and Paradigm.** During experiments monkeys were seated inside a primate chair, head-fixed and 58 cm away from a 21-inch LCD monitor inside a sound attenuating chamber. Visual stimuli, gaze (SRS Eye-link 1000 system), and fluid reward delivery were controlled by MonkeyLogic toolbox ([http://www.brown.edu/Research/monkeylogic/](http://www.brown.edu/Research/monkeylogic/)). The monkeys performed a feature-based reversal learning task that required covert spatial attention to one of two stimuli dependent on color-reward associations (**Fig 1A**). In contrast to color, other stimulus features (motion direction and stimulus location) were only randomly related to reward outcome – they were pseudo-randomly assigned on every trial (**Fig 1B**). Color-reward associations were reversed in an uncued manner between blocks of trials with constant color-reward association (**Fig 1C**). Each trial started with the appearance of a grey central point, which had to be fixated. After 0.5 - 0.9s, two 2° radius wide black/white gratings appeared 5° to the left and right of the central fixation point with 0.8 °/s motion inside the apertures drifting in opposite directions. Following another 0.4s the two stimulus gratings either changed color to black/green and black/red (Monkey K: black/cyan and black/yellow), or started moving at 1.20 cycles/degree in opposite directions up and down, followed after 0.5 - 0.9s by the onset of the second stimulus feature that had not been presented so far, e.g. if after 0.4s the grating stimuli changed color then after another 0.5 - 0.9s they started moving in opposite directions. Within the next 0.4 - 1s either the red and green stimulus dimmed for 0.3s followed by the dimming of the other stimulus after 0.55 s, or they dimmed simultaneously. The dimming represented the Go-cue to make a saccade to one of two response targets displayed 4° above and below the central fixation point. The monkeys kept central fixation until this dimming event occurred. A saccadic response following the dimming was only rewarded (with ~0.3ml fluid) if it was made in the direction of motion of the stimulus carrying the reward associated color and at the time that stimulus dimmed. The color-reward association was changed every 30-50 trials and 30-100 trials for Monkey H and Monkey K respectively. During task performance, a running average of 90% rewarded trials over the last 12 trials induced an un-cued block change.
Experimental Procedure. Monkey H and Monkey K did not receive either of the two drugs prior to the experiment. For each monkey, prior to the first week with drug/saline injections we obtained baseline performance. Monkey H started with PHA-543613, while monkey K started with the ABT-089 drug conditions before the drugs were reversed. Data was collected from Tuesday to Friday with two days pseudo-randomly assigned to drug injection (IM) and the remaining two days assigned to vehicle (saline) injections (IM). The assignments of drug days balanced the number of days of the week between drug and control condition to preclude prediction of when drugs versus vehicles were injected. The vehicle injections occurring between drug treatments were considered for analyses as control sessions. Drugs and vehicle were injected by a lab technician. The experimenter was blind to the treatment conditions. For each experimental session, subjects were given at least 50 minutes to perform the task. For PHA-543613 experiment, injection was administered 30±1 minute prior to start of the task. The time frame was chosen as an estimate based on prior (mostly rodent) studies (Wishka DG et al. 2006; Yang Y et al. 2013; Bali ZK et al. 2015; Kolisnyk B et al. 2015; Sadigh-Eteghad S et al. 2015). For ABT-089 experiment, the injection was done 10±1 minutes prior to the start of the task. This time frame was chosen based on previous non-human primate studies where the same drug was applied (Decker MW et al. 1997; Prendergast MA, WJ Jackson, et al. 1998). All sessions were conducted at the same time of the day. The selected doses for PHA-543613 experiment with Monkey H were 0.125 and 0.250 mg/kg. Once the optimal dose was determined for Monkey H, only the 0.250 mg/kg dose was used with Monkey K. These doses were chosen as an estimate from the rodent literature (Wishka DG et al. 2006; Bali ZK et al. 2015; Kolisnyk B et al. 2015; Sadigh-Eteghad S et al. 2015). The doses for the ABT-089 experiment (0.01 and 0.02 mg/kg) were chosen based on high and low values of the dose range previously tested in rhesus monkeys (ref). Initially, 0.04 mg/kg was selected as the higher dose for Monkey H, but discontinued after possible adverse side effects (nausea) could not be excluded. Once, the optimal dose was determined for Monkey H, the 0.02 mg/kg dose was used with Monkey K, however, upon observation of no improvement in the behavior and a slight tendency towards worse performance in one of the task components, the 0.01 mg/kg dose was administered to Monkey K. Experiments with PHA-543613 and ABT-089 could be analyzed for 8 and 12-week for monkey H, and for 2 and 4 weeks for monkey K. For Monkey H, we analyzed 15, 8, and 7 sessions for control, 0.250 mg/kg and 0.125 mg/kg dose of PHA-543613, respectively, and 20, 7, and 9 sessions for control, 0.02 mg/kg and 0.01 mg/kg dose of ABT-089, respectively. For Monkey K, we analyzed 7, 4, and 4 sessions for control, 0.02 mg/kg
and 0.01 mg/kg dose of ABT-089, respectively, and 3 and 4 sessions for control and 0.25 mg.kg for PHA-543613, respectively.

**High Pressure Liquid Chromatography (HPLC) Analysis of Blood Serum.** We used mass spectrometry HPLC analysis to identify the peak concentration and overall metabolism pattern of the drugs over time. Nine blood samples of 300 μl in total (baseline and 8 samples after injection) were extracted from a 10-year-old, 10 kg male rhesus macaque. The samples were taken at the following time points: 1 minute before drug injection (baseline), 9,15,25,40,70,100,160 & 220 minutes after injection. The higher drug dose (0.25 mg/kg) for PHA-534613 was considered for HPLC analysis while for ABT-089 the lower dose (0.01 mg/kg) was selected. Samples were centrifuged at 2000 rpm speed for about 40 minutes and after being spin filtered, stored for mass spectrometry HPLC processing. The procedure was successful for PHA-543613 (Fig. S1), However, no AB-089 signal was observed in any of the blood samples and as a result no blood serum analysis could be obtained. It was possible that the injected drug dose was too low or the drug became completely protein bound in the blood and therefore would not have been able to pass through the spin filter. In previous literature, the plasma exposure of ABT-089 was measured in baboons under both bolus intravenous (IV) injection and slow infusion in doses ranging 0.04-1 mg/kg (Chin CL et al. 2011).

On average, Monkey H worked for 74 and 60 minutes and Monkey K worked for 84 and 92 minutes during experimental sessions of PHA-543613 and ABT-089, respectively. Results from (Chin CL et al. 2011) and HPLC analysis of PHA-543613 suggested that the peak concentration and the subsequent drop in blood concentration were captured within the testing session time for both pharmacological agents.

**Data Analysis.** Analysis was done using Matlab (The Mathworks). To assess the effects of systematic injection of PHA-543613 and ABT-089 on attention and feature based reversal learning, different aspects of behavior were defined and quantified as described below. In some analyses, a moderately small number of data points existed in the drug condition which was considerably fewer than control. Therefore, data across all control and drug sessions were compared using non-parametric Wilcoxon rank sum test for evaluation of performance in different time windows, trial type subsets based on dimming event and number of reversal blocks and
rewarded trials. In addition, two-sample z-test was used for comparing proportions and randomization test was applied when correction for multiple comparison was needed.

**Temporal variation of drug effects on performance.** Blocks were categorized as learned and not-learned; the latter defined as blocks with no identified learning trials (the first trial which the ideal observer component of the model identifies for reliable learning to occur above chance performance) or having learning trials above 24 as computed by the expected maximization (EM). Performance for the analysis of temporal variation of drug effects was only done in learned reversal blocks. Trial by trial performance was estimated by using an Expectation Maximization algorithm (Smith AC et al. 2004). For details on implementation of EM algorithm in modelling the performance of subjects, see (Hassani SA et al. 2017). We tested drug effects at different time windows relative to the injection of the drug similar to previous studies of selective nAChR agonists with different plasma level half times to prevent overlooking shorter lasting effects (e.g. (Hahn B et al. 2003). Different overlapping time windows after the task started were selected to evaluate the temporal effects of drugs on behavior. The time windows included: 0-25, 12.5-37.5, 25-50, 37.5-62.5 minutes. **Table 3 and Table 4** show the number of learned blocks within each time window and during the entire session across all treatment conditions for Monkey H and Monkey K, respectively.

Dynamics of performance including learning speed and net increases in performance were measured via parameters of a hyperbolic ratio function fit to learning curves. The parameters of interest to compare between experimental and control sessions were $C_{50}$ (trial to reach half maximal of performance, exponent (slope) and $R_{max}$ (maximum increase in performance from baseline performance). Randomization procedure was carried out to test the significance of differences in the parameters of interest estimated by the hyperbolic-ratio function between drug and control conditions. The randomization procedure followed steps described in (Maris E and R Oostenveld 2007). The randomization was repeated 1000 times and the distribution of root of mean square error (RSME) of all estimated parameters was constructed. Any estimation that had RSME above 90 percentile of this distribution was excluded. The difference between the estimated parameter values were extracted as test statistics and the 97.5% and 2.5% percentiles of the null test statistics distribution was computed to conduct a two-tailed test at 0.05 alpha significance. These two values served as thresholds based on which the significance of the observed difference between the parameters of interest was determined. The proportion of values
Nicotinic sub-receptor specific modulation of learning and attention

within the null distribution larger than the observed test statistics was calculated as the p value of this randomization procedure.

**Distractor filtering.** Distracting effects of irrelevant stimuli were evaluated in trials were dimming of both stimuli occurred simultaneously. Here, performance was calculated as the proportion of correct choices across all blocks of a session. In comparison to trials where dimming of the two stimuli did not happen simultaneously, performance in the same dimming trial type required a higher level of attentiveness to filter distraction. All dimming trial types were presented with the same ratio i.e. 1/3 each.

**Motivation.** The motivation of subjects was studied in terms of total number of blocks performed and rewarded trials which would indicate the amount of earned fluid during the sessions. The proportion of learned to total reversal blocks were computed as well and compared to each other with two sample proportions z-test. The z score was computed based on the equation below (Zar JH 2010) where $p_1$ is the first proportion value, $p_2$ is the second proportion value. If the null hypothesis was true, then $p_1-p_2=0$. $P$ is the proportion of learned blocks calculated by pooling data from both control and drug conditions as shown by the following equation:

$$Z = \frac{(p_1 - p_2) - 0}{\sqrt{((p_1) \left(\frac{1}{n_1} + \frac{1}{n_2}\right)}}$$

**Results**

We obtained feature-based learning performance with a $\alpha_7$-nAChR agonist PHA-543613 in 19 sessions (monkey H= 8 sessions for 0.250 mg/kg and 7 sessions for 0.125 mg/kg dose), monkey K=4 sessions for 0.250 mg/kg; saline control sessions: 15/3 for monkey H and K, respectively), and with a $\alpha_4\beta_2$-nAChR agonist ABT-089 in 24 sessions (monkey H= 7 sessions for 0.02 mg/kg and 9 sessions for 0.01 mg/kg dose, monkey K=4 sessions for 0.02 mg/kg and 4 sessions for 0.01 mg/kg; saline control sessions: 20/7 for H and K, respectively).

**Overall Performance Effects of Selective nAChR**

Both nAChR agonists had a negligible influence on overall performance accuracy and motivation to perform the task. For PHA-543613 the overall performance accuracy was 77%, 77%, and 74% percent correct for the 0.25 mg/kg, 0.125 mg/kg and control conditions in monkey H, and 65%
and 63% percent correct for the 0.25 mg/kg and control conditions in monkey K. The different performance levels were not significantly different (for monkey H and K, all tests, z test, p>0.05). For ABT-089 the overall performance accuracy was 83%, 83%, and 80% percent correct for the 0.02 mg/kg, 0.01 mg/kg, and control conditions in monkey H, and 63%, 69%, and 65% percent correct for the 0.02 mg/kg, 0.01 mg/kg and control conditions in monkey K. The different performance levels were not significantly different (for monkey H and K, all tests, z test, p>0.05).

**nAChR Agonists Effects on Motivation and Reward Intake**

We estimated the motivation to perform the task by calculating the number of reversal blocks the animals engaged in across sessions with and without drug. For PHA-543613, we found that the number of reversal blocks performed during 0.25 mg/kg, 0.125 mg/kg, and control sessions were not significantly different for monkey H, or monkey K (all Wilcoxon ranksum tests, p>0.05). Similarly, for ABT-089, we found that the number of reversal blocks performed during 0.01 mg/kg, and control sessions were not significantly different for monkey H, or monkey K (all Wilcoxon ranksum tests, p>0.05). The only exception was for the high (0.02 mg/kg) dose for which monkey H performed fewer number of blocks compared to control sessions (Wilcoxon ranksum test, p=0.0255). However, during these sessions for monkey H the proportion of learned versus unlearned blocks with ABT-089 (0.02 mg/kg) treatment was significantly higher than control (z test, p=0.018). This higher proportion of learned to unlearned blocks could account for the lower number of reversal blocks performed in the same sessions and are unlikely a reflection of drug effects on motivation.

Consistent with the previous results, we found that the overall reward intake per session, calculated as the total number of rewarded choices per session, was similar between drug and control experiments for both drugs. For PHA-543613 the average number of rewarded trials per session in the 0.250 mg/kg, 0.125 mg/kg and control conditions was 342+/−30.47, 401+/−61.99 and 354+/−26.51 for monkey H, and 245+/−14.04 and 248+/−13.42 for monkey K (all Wilcoxon ranksum tests, p>0.05). For ABT-089 the average number of rewarded trials per session in the 0.02 mg/kg, 0.01 mg/kg and control conditions was 212+/−17.13, 304+/−35.32 and 264+/−17.79 for monkey H and 216+/−21.86, 189+/−26.36 and 205+/−21.90 for monkey K (all Wilcoxon ranksum tests, p>0.05).
tests, p>0.05). Taken together, neither nAChR drug modulated overall motivation and reward intake at the doses tested.

**Effects of nAChR Agonists on Feature-based Learning**

We next calculated whether the drug treatment facilitated learning of feature values. To this end, we computed the learning curves for each reversal block using an ideal observer statistics that calculated how consistently the monkeys choices were rewarded across sequences of trials (see Methods, and (Hassani SA et al. 2017)). We then fit the resulting learning curves with a hyperbolic ratio function to extract the trial number at which the learning reached 50% of the maximum asymptotic performance value, which could be early or late, corresponding to fast versus slow learning (Fig. S2). We term this learning trial the “L50” (in analogy to the C50 for contrast sensitivity measurements using the same function). L50’s for the overall learning curves did not differ for either monkey, dose and drug condition, as expected from the similar overall performance (see above). Given the known temporal decay of the receptor agonists over the course of 1-2 h sessions (see Methods and Fig. S1), we thus compared the distribution of L50’s for learning curves obtained in successive 25 minute time intervals following systemic drug or saline injections.

For the PHA-543613 treatment, we found that learning speed as indexed by the L50 parameters were not different between the 0.125 mg/kg dose and control injections for Monkey H in either 25 minute time window after drug injection (randomization test, p>0.5) (Fig. 2A,B). However, both monkeys showed faster learning speeds with the higher dose during specific time periods with 0.25 mg/kg PHA-543613 compared to the saline control injections. At this higher dose, monkey H showed in the first 25 minute a significantly earlier average L50 in the drug versus control conditions (randomization test, p=0.0341) (Fig. 2A, left panel). No later time epoch showed different average L50’s (randomization tests all n.s.). Monkey K showed a significant earlier average L50 after drug versus control injection conditions in T2 (12.5-37.5 minute interval) (randomization, p=0.022) and in the T3 (25-50 minute time interval) (randomization, p=0.0123) (Fig. 2B, left panel). No other time epoch showed an L50 effect for drug versus control conditions (randomization tests all n.s.).

In contrast to the PHA-543613 treatment effects, ABT-089 did not increase the learning speed at any 25 minute time interval following injection (Fig. 2C,D). Across all statistical comparisons, we found only for the high 0.02mg/kg ABT-089 dose a significant modulation at the T2 (12.5-37.5...
Nicotinic sub-receptor specific modulation of learning and attention

minute time interval), evident in slower learning in the drug condition (mean L$_{50}$ of 6.02 vs. 4.34 for drug and control condition, respectively; Bootstrap significance p=0.02 Fig. 2C, right panel). At all other conditions the L$_{50}$’s in drug and control conditions were indistinguishable (for monkey’s H and K, all comparisons n.s.; the 0.02 mg/kg dose, T1 (0-25 minute time interval) in monkey K was not tested because too few learned blocks were available for analysis).

In addition to the L$_{50}$, we also characterized the plateau level of performance of the learning curves using the R$_{\text{max}}$ parameter of the hyperbolic ratio fits and found inconsistent results. Across the treatment with PHA-543613 or ABT-089, at low and high doses, and at either of four different time epochs since injection we found that for Monkey H, R$_{\text{max}}$ was lower at T1 (0-25 minute window) after 0.02 mg/kg ABT-089 injection (randomization test, p=0.0311). For Monkey K, R$_{\text{max}}$ was lower in PHA-543613 0.250 mg/kg condition than control condition during the T2 (12.5-37.5 minute window) (randomization test, p=0.0379 Fig. S5-A, left panel). In the same time window, ABT-089 0.01 mg/kg led to higher R$_{\text{max}}$ performance (randomization test, p = 0.0174).

Effects of nAChR Agonists on Attentional Filtering of distraction

Our feature-based reversal learning task required monkeys to make a saccadic choice (up-/downwards saccade) to a transient dimming event of the stimulus with the reward associated color. We used this choice event to manipulate the attentional filtering demands of the task by having both stimuli dimming at the same time in one-third of the trials (Fig. 1). In these trials, the dimming of the distractor stimulus had to be attentionally filtered in order to process the dimming of the target stimulus that had the reward associated color. In the other two thirds of trials the target stimulus dimmed before or after the dimming of the distractor stimulus, and thus required filtering the dimming event in the distractor without concomitant processing of a dimming event of the target. To compare the drug effects on attentional filtering we compared the proportion of erroneous choices to the motion direction of the distractor separately for the condition with the target dimming before, after, and simultaneously with the distractor (Fig. 3A,C; for detailed data for each monkey and subcondition, please see Fig. S3).

For the PHA-543613 treatments, the average performance accuracy in these conditions were indistinguishable from control performance at the 0.125 mg/kg and 0.25mg/kg conditions for monkey’s H and K (Wilcoxon ranksum tests for each dose and monkey, p>0.05) (Fig. 3A).
Nicotinic sub-receptor specific modulation of learning and attention

In contrast, ABT-089 treatment yielded lower errors than control when both stimuli dimmed simultaneously in both monkeys, but not in other trials types in which the target dimmed before or after the distractor dimmed (Fig. 3B). In Monkey H, ABT-089 treatment with 0.02 mg/kg led to reduced erroneous distractor choices in trials with simultaneous dimming than control treatment (Wilcoxon ranksum test, $p=0.031$). Drug versus control performance was similar for the other conditions with the dimming occurring before or after the distractor. There was no significant drug effect on performance with and without filtering demands with 0.01 mg/kg ABT-089 treatment. In Monkey K, ABT-089 treatment with 0.01 mg/kg there was a trend for reduced erroneous distractor choices in trials with simultaneous dimming (16% erroneous choices) than control treatment (27% erroneous choices) (Wilcoxon ranksum test, $p=0.16$) (Fig. 3B). There was no performance difference when the target dimmed before or after distractor (Wilcoxon ranksum test, n.s.). At the higher 0.02 mg/kg dose the performance was not significantly different than control for trials with filtering demands (Wilcoxon ranksum test, $p=0.32$).

The results showed the same direction of the ABT-089 drug effect to improve performance during trials with larger filtering demands, but not in other trial types in Monkey H at 0.02 mg/kg, and in Monkey K at 0.01 mg/kg. We therefore pooled the data from Monkey H ABT-089 (0.02 mg/kg) and Monkey K (0.01 mg/kg) to increase statistical power for inferential analysis. This pooling showed a highly significant difference between drug and control sessions only when both stimuli dimmed simultaneously (Wilcoxon ranksum, $p=0.008$) (black marker in Fig. 3B). No significant difference was observed with any other dimming conditions (Wilcoxon ranksum, $p>0.1$). Taken together, ABT-089, but not PHA-543613, was associated with improved attentional filtering.

Comparison of Baseline Performance Levels

We tested for PHA-543613 and ABT-089 drug effects in experimental sessions that were separated by several weeks (see Methods). We therefore tested whether the overall performance levels remained similar between testing periods for either drug. To this end we extracted the control performance during the PHA-543613 testing sessions, and compared them to the ABT-089 testing sessions. We found that for both monkeys the asymptotic performance levels (the $R_{\text{max}}$ parameter of the hyperbolic ratio fits) were similar for PHA-543613 and ABT-089 testing sessions (randomization tests, all $p>0.05$). With regard to learning, we found that monkey H showed faster learning during the ABT-089 control sessions than in the PHA-543613 control sessions (randomization, $p=0.0133$). There was no difference in learning speed in control
sessions for monkey K (randomization test, p>0.05). We performed the same control session comparison for the attentional filtering performance. We found for monkey K that control performance was statistically indistinguishable for the different conditions (target dimming before, after, or simultaneously with distractor) (randomization tests, all p>0.05). Monkey H showed similar performance in PHA-543613 and ABT-089 control testing sessions when the target dimmed before or simultaneously with the distractor, but was more accurate for in the ABT-089 control sessions when the target dimmed after the distractor (see Supplementary Fig. 3). In summary, these findings indicate that despite an overall consistent performance pattern in monkey K, monkey H showed selected improvements during the ABT-089 testing sessions.

Effects of Selective nAChR on Error Types and Reaction Times
The effects of PHA-543613 on learning and the effects of ABT-089 on attentional filtering might be mediated by proneness for specific behavioral errors, or by trading accuracy with reaction times (speed-accuracy trade-offs). To address the first factor, we quantified three different types of errors. First, we considered perseveration errors, estimated as the proportion of successive unrewarded choices following a correct choice. Second, we counted the number of fixation breaks in the covert attention period that started with the onset of the stimulus color and motion, and ended with the dimming event prior to the choice. These errors might index lapses in attentional control to prevent looking at the peripheral stimuli. Third, we calculated the overall number of fixation breaks that occurred early in the trial, prior to the color and motion onset, which might indicate overall oculomotor tone or motivational factors. We found that the occurrences of neither of these three error types varied with PHA-543613, or ABT-089 at low, or high doses in Monkey H or Monkey K (all Wilcoxon ranksum tests comparing each drug condition to their control conditions, p>0.05).

To address possible drug effect on reaction time speed, we calculated the saccadic reaction times following the choice event. We found that none of the drugs resulted in statistical changes in reaction times at low or high doses in Monkey H or Monkey K (all pairwise Wilcoxon ranksum tests, p>0.2). Average reaction times across drugs and experimental conditions ranged from 188 ms to 197 in Monkey H, and from 232 to 247 ms in Monkey K.

Discussion
We found that two sub-receptor specific nicotinic agonists have dissociable effects on the learning speed and the attentional filtering performance of two healthy rhesus macaques. The selective α7 nAChR agonist PHA-543613 selectively enhanced the speed of learning feature values, but did not modulate how salient, distracting information was filtered from ongoing choice processes. In contrast, the selective α4β2 nAChR agonist ABT-089 did not affect learning speed but reduced the number of intrusions of distractor information in the condition that required the attentional filtering of a salient distractor event while maintaining the focus on a target stimulus. This double dissociation of learning versus filtering processes was evident for each monkey, and only for one of two drug doses tested. Moreover, these dose-dependent behavioral effects were evident in the absence of systematic changes in overall performance, reward intake, motivation to perform the task, perseveration tendencies, or reaction times. Overall, we believe that these findings provide strong evidence for sub-receptor specific nicotinic mechanisms supporting higher level attention and learning functions in the primate brains.

**α7 nAChR specific enhancement of cognitive flexibility to adjust to behavioral feedback.**

We found that at the higher dose, the α7 agonist gave rise to faster learning following feature-reward reversals in both monkeys (Fig. 2). The learning effect disappeared within 25 minutes and 50 minutes for Monkey H and K, respectively. To understand the temporal specificity of this effect we performed HPLC analysis of plasma concentration level temporal decay of PHA-543613 as an indirect estimate of neurally available drug concentration. We found that our monkeys started performance within minutes after the peak plasma concentration levels and that after 50 minutes of task performance the plasma concentration levels had dropped to below half maximum concentration level (Figure S1). We believe this rapid kinetic underlies the short-lived improvement on learning speed with the α7 agonist PHA-543613.

The observed faster reversal learning indexes enhanced flexibility to adjust to changing behavioral feedback and thus reflects a genuine improvement of attentional control and learning from error feedback (Kehagia AA et al. 2010; Balcarras M et al. 2016; Izquierdo A et al. 2017). Such enhanced flexibility can have multiple causes. Previous cholinergic modulation studies suggest that enhanced flexibility to adjust to behavioral challenges are mediated by an enhanced tonic mode of cholinergic action in prefrontal cortex (Sarter M et al. 2016). According to this model cholinergic transients are triggered by unexpected increases in performance demands. Enhanced ACh availability is then allowing α7 nAChRs action to support more robust neural goal
Nicotinic sub-receptor specific modulation of learning and attention

representations. More robust goal representations translate into behavior that more effectively ‘follows-through’ to achieve the goal. A key observation of this model is that in rodent prefrontal (peri- and infralimbic) cortex ACh transients occur during a sustained attention task in correct trials that followed misses or correct rejections (Parikh V et al. 2007; Howe WM et al. 2013). These trials are similar to the post-reversal trials in our task in which the animal experiences unexpected omissions of reward after choices made to the no longer reward associated stimulus color (causing negative prediction errors), and in subsequent trials when the animals receive reward to the previously unrewarded stimulus color. Consequently, our results support the suggestion that stronger α7 receptor activation enhances the robustness of neural goal representations and thereby facilitating to “follow-through” in adjusting attentional set and behavior after a reward-reversal. This receptor specific interpretation is consistent with the finding in rodents that α7 nAChRs action prolongs the duration of elevated ACh to >10 sec following cholinergic transients in the prefrontal cortex (Parikh V et al. 2010). Such longer durations are likely beneficial in our task to successfully follow-through with adjusting the attentional set across multiple post-reversal trials, each lasting ~4-6 sec.

The neural effect underlying the proposed α7 action might well involve changes in synaptic connection weights among neurons encoding the newly rewarded stimulus as suggested by reversal learning models (Fusi S et al. 2007; Rombouts JO et al. 2015). Intriguingly, such short-term plasticity might be particularly supported by the α7 receptor which is associated specifically with enhanced intracellular calcium signaling, spike-timing dependent plasticity and long-term potentiation of synapses in medial temporal cortex and cortico-amygdala circuits (Gu Z and JL Yakel 2011; Gu Z et al. 2012; Jiang L et al. 2016). We believe that similar α7 mediated learning might be effective in fronto-striatal circuits that are critical for feature-based attention and reversal learning.

A possible complementary route for how α7 specific activity could support reversal learning in our task is by amplifying other neurotransmitter systems. Previous studies have shown that in prefrontal cortex, striatum and hippocampus α7-receptor activation triggers release of glutamate (Jones IW and S Wonnacott 2004; Dickinson JA et al. 2008; Bortz DM et al. 2013), GABA (Arnaiz-Cot JJ et al. 2008), norepinephrine (Kennett A et al. 2012), and dopamine (Pidoplichko VI et al. 1997; Livingstone PD and S Wonnacott 2009; Quarta D et al. 2009). Among these co-activated neurotransmitters, dopamine and norepinephrine have long been implicated to enhance cognitive
Nicotinic sub-receptor specific modulation of learning and attention

flexibility in reversal learning and attentional set shifting tasks (van der Meulen JA et al. 2007; Kehagia AA et al. 2010; Wallace TL and D Bertrand 2013). Consequently, activating α-2A norepinephrine receptors could be one route a7 could improve learning. Strong support for this scenario comes from a previous study in which we found a similar faster reversal learning performance at optimal doses of the α-2A noradrenergic agonist Guanfacine (Hassani SA et al. 2017). In that study, an increased reversal learning speed was the most prominent behavioral effect during prolonged testing at effective doses.

Our study adds an important data point to the five existing studies testing selective nAChR’s agonists on set shifting or reversal performance in monkeys (Table 1, Table’s S1, S2) by illustrating that selective α7 nAChR activation specifically enhanced the learning speed without affecting other attentional markers of task performance. This effect was dose specific. A previous study reported detrimental set shifting effects of an α7 receptor agonist at a dose at which the agonist enhanced short term memory maximally (Gould RW et al. 2013). We believe that our dose specific finding suggests that activating α7 specific mechanisms can enhance learning flexibility, but that this effect occurs independently of strengthening recurrent short-term memory activity. Consistent with this interpretation it has been acknowledged that strong short-term memory that might be needed for bridging long delays in delayed match-to-sample tasks conflicts with the demands to flexibly shift between attended stimulus features needed to succeed with reversal learning (Thiele A and MA Bellgrove 2018).

To summarize, our finding of dose specific enhanced reversal learning is consistent with α7 specific modulation of the duration of elevated cholinergic tone following cholinergic transients putatively triggered by reward reversals. The working mechanism might involve α7 mediated short-term strengthening of synaptic connections in prefrontal cortex or striatum but may also include the amplification of other neurotransmitter actions, particularly the norepinephrinergic receptors.

**α4β2 specific filtering of distraction and stabilizing of goal representations.**
Our task varied the attentional filtering demands and found that the α4β2 agonist, but not the α7 agonist, facilitated attentional filtering of a distractor event occurring at the same time as the choice event of the target stimulus (Fig. 3). ABT-089, but not PHA-543613, reduced the choice errors by half compared to the control condition, strongly suggesting that enhanced distractor
Nicotinic sub-receptor specific modulation of learning and attention

Filtering is specifically mediated by α4β2 mechanisms. Prior NHP studies demonstrated distractor filtering benefits with α4β2 agonists using delayed match-to-sample tasks (see Table 2 and Table S2). However, these NHP studies did not include α7 nAChR modulation to allow a direct comparison between sub-receptor specific effects with the same subjects and experiment. Our receptor-specific dissociation is consistent with suggestions of α4β2 sub-receptor specific distractor modulation in rodents using a sustained attention task (SAT) (Howe WM et al. 2010). The SAT requires rodents to memorize a cue location and either respond or withhold responding to that location. Distracting light flashes between cue and response intervals are more tolerated during α4β2 agonist action than α7 agonist action (Howe WM et al. 2010; St Peters M et al. 2011). Our study extends these insights in receptor-specific facilitation of distractor filtering to the NHP domain and a feature-based attention paradigm.

In fact, we are not aware of other NHP paradigms that succeeded to isolate a distractor-filtering specific drug effect in the absence of confounding short-term memory manipulations. We believe this is a significant advance of the field. Despite the similarity of the functional benefits of α4β2 action in light of attentional filtering demands in the DMTS (in NHP and rodents), the SAT (in rodents), and the feature-based attentional learning task we deployed, there are important differences of the nature of the distracting events that are affected in these different tasks. Firstly, prior NHP studies using ABT-089 indicate that flashing distracting random lights in the first 3s of the delay of a delayed match to sample task are not impairing behavior when the matching stimulus follows ~10 sec. after the cue (Prendergast MA, WJ Jackson, et al. 1998). This finding indicates that with good dosing of α4β2 agonists the cue (the DMTS sample stimulus) is more robustly represented in short-term memory, as has been directly documented in prefrontal cortex neurons (Sun Y et al. 2017). The described distractor filtering during short term memory delays in these tasks is similar to the attentional filtering condition in our task in which the distractor stimulus undergoes a luminance change just prior the target choice event, i.e. when the target representation had to be selectively maintained while a single salient event distracted ongoing attention. However, in contrast to the prior DMTS NHP studies (Prendergast MA, WJ Jackson, et al. 1998; Buccafusco JJ et al. 2007), in our 'target after distractor event' condition neither the α4β2, nor α7 agonist improved performance of our animals. We believe that we did not find a distractor effect in this condition because the subjects did not need to rely on a purely internally maintained short-term memory of the target feature (the rewarded color) but could refocus attention to the target stimulus even when the distractor captured attention. Thus, α4β2 agonists
Nicotinic sub-receptor specific modulation of learning and attention

could not reveal its role in enhancing the internal goal representation in this condition, as long as there was sufficient inhibitory behavioral control to not respond to the distracting event when it occurred before the choice event in the target stimulus.

We did find, however, that good dosing of α4β2 agonists enhanced filtering distracting events when they co-occurred with the target event. Such simultaneous perceptual events are the hallmarks of perceptual conflict studies of cognitive control (Alexander WH and JW Brown 2011) and to our knowledge have not been tested in NHPs with selective nAChR agonists. We believe the most parsimonious explanation for this effect is the selective stabilization of goal–relevant feature representations as recently suggested in the framework of neurotransmitter control of neural attractor dynamics (Thiele A and MA Bellgrove 2018). In this framework, increased distractor filtering follows from stronger recurrent dynamic activity of neural circuits representing the attended target feature. Consistent with this scenario, active α4β2, but not α7, nAChRs have been shown to gain modulate the amplitude of phasic cholinergic increase in prefrontal cortex when encountering unexpected outcomes (Parikh V et al. 2007; Parikh V et al. 2010).

Taken together, our findings provide strong converging evidence for the assertion that α4β2 acts as gain modulator for the strength of prefrontal cholinergic transient activity, while α7 receptor activation mediates longer durations of cholinergic tone in prefrontal cortex (Parikh V et al. 2010). We believe that future studies could test this model by measuring the influence of selective nAChR’s on neural activity dynamics in the prefrontal cortex and associated network nodes in the striatum.

Implications of a functional double dissociation of α7 and α4β2 receptor action on learning and attention.

During natural behavioral without neurochemical interventions, both α7 and α4β2 receptor subtypes are activated when acetylcholine becomes available through stimulation of the medial forebrain bundle (Ballinger EC et al. 2016). By applying systemic nAChR agonists we have biased the natural balance of α7 and α4β2 action towards either sub-receptor action. By revealing a functional double dissociation of biasing the balance to either α7 or α4β2 we believe our findings reveal that these sub-receptors tap into distinct operations in the neural circuit that have been underestimated in previous studies. A recent comprehensive survey of cholinergic modulation of attention concluded that α7 and α4β2 actions might tap into similar functionality to stabilize goal
Nicotinic sub-receptor specific modulation of learning and attention

represents in the prefrontal cortex, but that α7 receptor action is less potent than α4β2 action in the PFC than in memory related circuits (Thiele A and MA Bellgrove 2018). While our finding is consistent with this view, it raises the possibility that both sub-receptor systems play fundamentally different roles in neural circuits that are camouflaged by their co-modulation in most natural conditions and by their common action to trigger NMDA dependent increases in excitability (Yang Y et al. 2013; Sun Y et al. 2017).

In addition to the alleged distinct roles within the same (prefrontal cortex) circuit, the observed double dissociation would also be consistent with a scenario in which α7 receptor action and α4β2 affect different circuits, each contributing uniquely to learning and to attentional filtering (Chudasama Y and TW Robbins 2006). We believe that this suggestion is unlikely explaining the observed functional dissociation, given that both sub-receptors are widely available across all major cortical and subcortical systems relevant for attentional control and reversal learning (Figure S4) (Gotti C et al. 2006). However, it might soon be possible to discern more subtle sub-receptor density differences with recent advances in whole brain PET imaging of α7 and α4β2 receptor availability (Teodoro R et al. 2015; Hillmer AT et al. 2017).

Such differences in sub-receptor specific expression density of α7 and α4β2 nAChRs have been a hallmark of studies in clinical populations. A most prominent example is schizophrenia, where patients have been repeatedly found to show reduced α7 receptor expression and availability in anterior cingulate cortex, frontal cortex and hippocampus (Martin-Ruiz CM et al. 2003; Wong DF et al. 2018). Consistent with these findings, α7 is implicated in the pathophysiology and the cognitive inflexibility symptoms of schizophrenia, as well as of Alzheimer’s diseases (Thomsen MS et al. 2010; Toyohara J and K Hashimoto 2010). Our findings are remarkably consistent with these findings of α7 associated behavioral flexibility, and suggest that the NHP animal model will be essential to understand the underlying mechanisms of altered nAChR functioning in schizophrenia and Alzheimer’s dementia.

Conclusion
Our results document a double dissociation of cholinergic sub-receptor specific contributions to higher-order learning and attention functions in the non-human primate. We believe that these findings will reinforce ongoing efforts in developing drugs for alleviating the symptoms in schizophrenia and Alzheimer’s, as well as in ADHD and various other neuropsychiatric conditions.
in which behavioral flexibility and attentional focusing is compromised together with altered α7 and α4β2 signaling (Millan MJ et al. 2012; Bertrand D et al. 2015).

Acknowledgments
This work was supported by a grant from the Canadian Institutes of Health Research, CIHR Grant MOP_102482 (T.W.). The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of this manuscript. The authors would like to thank Hongying Wang for technical support.

Competing interests: The authors declare no competing interests.

Figure Legends

Figure 1. Feature-based reversal learning task. (A) The task requires centrally fixating and covertly attending one of two grating stimuli that has the color associated with reward. To obtain reward the animal had to saccade in the up-/downward direction of the motion direction of the attended stimulus. The saccadic choice had to be made within 0.5 s following a dimming of the target stimulus. The dimming served as a Go-signal for the saccadic choice. In three attentional filtering conditions, the target Go-signal could either occur (1) in the target first, i.e. before the distractor, (2) in the target stimulus second, after the dimming occurred in the distractor stimulus, or (3) the dimming event occurred simultaneously in target and distractor (indicated in dashed box). (B) Three features characterize each stimulus – color, location, and motion direction. Only the color feature is directly and consistently linked to reward outcome. (C) The task is a reversal learning task, whereby only one color at a time is rewarded. This reward contingency switches repeatedly and unannounced across blocks of trials.

Figure 2. Sub-receptor specific effects on reversal learning speed. (A) Left: Distribution of p values from Bootstrap analysis of learning speed at four different time windows from the time of
Nicotinic sub-receptor specific modulation of learning and attention

injection of PHA-543613 or vehicle for Monkey H. The solid (dashed) line denotes the statistical comparison of learning speed between 0.125 (0.250) mg/kg PHA-543613 and the vehicle control condition. P values larger than three (-log(0.05)) denote a significantly different learning speed between drug and control condition. Time windows T1 to T4 refer to 0-25, 12.5-37.5, 25-50 and 37.5-62.5-minute time windows relative to the beginning of the testing session. Testing sessions started 30 min. and 10 min. following drug/vehicle injection during PHA-543613 and ABT-089 experiments, respectively. Right: The learning curves for Monkey H across control performance (black), the average performance in the 0.25mg/kg PHA condition (blue), and within the time window T1 (red), which revealed a significant faster learning in the bootstrap analysis (see left panel). (B) Same format as A for Monkey K, showing significant faster learning with 0.250 mg/kg PHA-543613 in the time windows T2 and T3 (red solid and dashed lines). (C) Same format as A for Monkey H and injection of ABT-089, showing no learning improvement, but a significantly decreased learning speed at time window T2 with the lower (0.01 mg/kg) dose of ABT-089. (D) Same format as C for Monkey K, showing no significant effect of ABT-089 on learning speed at any time window. Monkey K’s baseline vehicle control condition is from the PHA-543613 control (?) sessions. Error bars denote standard error of the mean.

Figure 3. Sub-receptor specific effect on performance with different degrees of attentional filtering requirements. (A) Y-axis: Proportion of incorrect choices in trials when the Go/No-Go choice signal occurred in the target stimulus before the distractor (left column), at the same time as the distractor (middle column), and after the distractor (right column). The demand of attentional filtering of the distractor event is strongest when distractor and target change at the same time (middle column). The x-axis denotes the 0.125 mg/kg dose of the α7 agonist PHA-543613 and the control condition (saline injections). The black marker denotes the average across Monkey H (light grey) and Monkey K (dark grey). Error bars are standard errors of the mean. (B) Same format as (A) for the results obtained with the α4β2 agonist ABT-089. There was a significant improved performance across monkeys for the condition with enhanced attentional filtering requirements with the α4β2 agonist ABT-089. The x-axis denotes 0.02 mg/kg and 0.01 mg/kg doses for Monkey H and Monkey K respectively (Wilcoxon ranksum, p=0.008, grey shaded panel in A), but not in any other condition.
Nicotinic sub-receptor specific modulation of learning and attention

Figure S1. Measured PHA-543613 plasma exposure (mean ± standard deviation) in Monkey S. HPLC analysis of blood serum obtained over a period of 220 minutes after IM injection of 0.250 mg/kg dose.

Figure S2. Parameters of hyperbolic ratio function fit to an example learning curve. The \( L_{50} \) parameter indexes the trial at which the animal reached half maximal performance (in this example, trial 6). The \( R_{\text{max}} \) parameter is the difference between baseline and maximal performance indicated by lower and upper dash lines respectively.

Figure S3. Average Performance with different degrees of attentional filtering requirements for each monkey, drug, and dose. (A,B) For ABT-089, proportion of incorrect choices in trials when the Go/No-Go choice signal occurred in the target stimulus before the distractor (left column), at the same time as the distractor (middle column), and after the distractor (right column). The demand of attentional filtering of the distractor event is strongest when distractor and target change at the same time (middle column). The x-axis denotes the different drug and control conditions. Results are shown separately for Monkey H (A) and Monkey K (B), respectively. Error are standard errors of the mean. (C,D) Same format as (A,B) for the \( \alpha_7 \) agonist PHA-543613. (Wilcoxon ranksum, \( p=0.031 \)).

Figure S4. Suggestive localization of nACh receptors in cortical and sub-cortical areas based on results from human and non-human primate studies. These results were obtained via in-situ hybridization and immunocytochemistry techniques (Cimino et al., 1992; Kulak et al., 2006; Quik et al., 2000; Quik et al., 2005; Spurden et al., 1997; Han et al., 2000; Han et al., 2003).

References

Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. 2009. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 89:73-120.
Alexander WH, Brown JW. 2011. Medial prefrontal cortex as an action-outcome predictor. Nature neuroscience. 14:1338-1344.
Nicotinic sub-receptor specific modulation of learning and attention

Arnai-Cot JJ, Gonzalez JC, Sobrado M, Baldelli P, Carbene E, Gandia L, Garcia AG, Hernandez-Guijo JM. 2008. Allosteric modulation of alpha 7 nicotinic receptors selectively depolarizes hippocampal interneurons, enhancing spontaneous GABAergic transmission. Eur J Neurosci. 27:1097-1110.

Balcanas M, Arditi S, Kapting D, Everling S, Womelsdorf T. 2016. Attentional Selection Can Be Predicted by Reinforcement Learning of Task-relevant Stimulus Features Weighted by Value-independent Stickiness. J Cogn Neurosci. 28:333-349.

Bai ZK, Inkeller J, Csurgyorok, Bruszt N, Horvath, Hernadi I. 2015. Differential effects of alpha7 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models. Behav Brain Res. 278:404-410.

Ballinger EC, Ananth M, Talmage DA, Role LW. 2016. Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron. 91:1199-1218.

Bertrand D, Lee CH, Flood D, Marger F, Donnelly-Roberts D. 2015. Therapeutic Potential of alpha7 Nicotinic Acetylcholine Receptors. Pharmacol Rev. 67:1025-1073.

Bortz DM, Mikkelsen JD, Bruno JP. 2013. Localized infusions of the partial alpha 7 nicotinic receptor agonist SSR180711 evoke rapid and transient increases in prefrontal glutamate release. Neuroscience. 255:55-67.

Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, Decker MW, Donnelly-Roberts D, Elliott RL, Gopalakrishnan M, Holladay MW, Hui YH, Jackson WJ, Kim DJ, Marsh KC, O'Neill A, Prendergast MA, Ryther KB, Sullivan JP, Arneric SP. 1997. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav. 57:231-241.

Buccafusco JJ, Jackson WJ, Gattu M, Terry AV, Jr. 1995. Isoarecolone-induced enhancement of delayed matching to sample performance in monkeys: role of nicotinic receptors. Neuroreport. 6:1223-1227.

Buccafusco JJ, Terry AV, Jr. 2009. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol. 78:852-862.

Buccafusco JJ, Terry AV, Jr., Decker MW, Gopalakrishnan M. 2007. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol. 74:1202-1211.

Chin CL, Carr RA, Llano DA, Barret O, Xu H, Batis J, Koren AO, Seibyl JP, Marsh KC, Tamagnan G, Decker MW, Day M, Fox GB. 2011. Pharmacokinetic modeling and [(1)(2)(3)]5-IA-85380 single photon emission computed tomography imaging in baboons: optimization of dosing regimen for ABT-089. J Pharmacol Exp Ther. 336:716-723.

Chudasama Y, Robbins TW. 2006. Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol. 73:19-38.

Decamp E, Schneider JS. 2006. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. Eur J Neurosci. 24:2098-2104.

Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW, Lin NH, Li Y, Daanen JF, Buccafusco JJ, Prendergast MA, Jackson WJ, Arneric SP. 1997. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther. 283:247-258.

Deutsch JA. 1971. The cholinergic synapse and the site of memory. Science. 174:788-794.

Dickinson JA, Kew JN, Wonnacott S. 2008. Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms. Mol Pharmacol. 74:348-359.

Fusi S, Asaad WF, Miller EK, Wang XJ. 2007. A neural circuit model of flexible sensorimotor mapping: learning and forgetting on multiple timescales. Neuron. 54:319-333.
Nicotinic sub-receptor specific modulation of learning and attention

Gotti C, Zoli M, Clementi F. 2006. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci. 27:482-491.

Gould RW, Garg PK, Garg S, Nader MA. 2013. Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history. Neuropharmacology. 64:479-488.

Gu Z, Lamb PW, Yakel JL. 2012. Cholinergic coordination of presynaptic and postsynaptic activity induces timing-dependent hippocampal synaptic plasticity. JNeurosci. 32:12337-12348.

Gu Z, Yakel JL. 2011. Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron. 71:155-165.

Hahn B, Sharples CG, Wonncacott S, Shoiba M, Stolerman IP. 2003. Attentional effects of nicotinic agonists in rats. Neuropharmacology. 44:1054-1067.

Hassani SA, Oemisch M, Balcarras M, Westendorff S, Ardid S, van der Meer MA, Tiesinga P, Womelsdorf T. 2017. A computational psychiatry approach identifies how alpha2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque. Scientific reports. 7.

Hillmer AT, Li S, Zheng MQ, Scheunemann M, Lin SF, Nabulsii N, Holden D, Pracitcho R, Labaree D, Ropchan J, Teodoro R, Deuether-Conrad W, Esterlis I, Cosgrove KP, Brust P, Carson RE, Huang Y. 2017. PET imaging of alpha7 nicotinic acetylcholine receptors: a comparative study of [(18)F]ASEM and [(18)F]DBT-10 in nonhuman primates, and further evaluation of [(18)F]ASEM in humans. Eur J Nucl Med Mol Imaging. 44:1042-1050.

Howe WM, Berry AS, Francois J, Gilmour G, Carp JM, Tricklebank M, Lustig C, Sarter M. 2013. Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J Neurosci. 33:8742-8752.

Howe WM, Ji J, Parikh V, Williams S, Mocaer E, Trocme-Thibierge C, Sarter M. 2010. Enhancement of attentional performance by selective stimulation of alpha4beta2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology. 35:1391-1401.

Izquierdo A, Brigman JL, Radke AK, Rudebeck PH, Holmes A. 2017. The neural basis of reversal learning: An updated perspective. Neuroscience. 345:12-26.

Jiang L, Kundu S, Lederman JD, Lopez-Hernandez GY, Ballinger EC, Wang S, Talmage DA, Role LW. 2016. Cholinergic Signaling Controls Conditioned Fear Behaviors and Enhances Plasticity of Cortical-Amygdala Circuits. Neuron. 90:1057-1070.

Jones IW, Wonncacott S. 2004. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci. 24:11244-11252.

Jones KM, McDonald IM, Bourin C, Olson RE, Bristow LJ, Easton A. 2014. Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats. Psychopharmacology. 231:673-683.

Kehagia AA, Murray GK, Robbins TW. 2010. Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol. 20:199-204.

Kennett A, Heal DJ, Wonncacott S. 2012. Pharmacological differences between rat frontal cortex and hippocampus in the nicotinic modulation of noradrenaline release implicate distinct receptor subtypes. Nicotinic Tob Res. 14:1339-1345.

Kolinsnyk B, Al-Onaiz MA, Prado VF, Prado MA. 2015. alpha7 nicotinic ACh receptor-deficient mice exhibit sustained attention impairments that are reversed by beta2 nicotinic ACh receptor activation. Br J Pharmacol. 172:4919-4931.

Livingstone PD, Wonncacott S. 2009. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem Pharmacol. 78:744-755.

Maris E, Oostenveld R. 2007. Nonparametric statistical testing of EEG- and MEG-data. J Neurosci Methods. 164:177-190.
Nicotinic sub-receptor specific modulation of learning and attention

Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, Perry EK, Court JA. 2003. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biological psychiatry. 54:1222-1233.

McLean SL, Grayson B, Idris NF, Lesage AS, Pemberton DJ, Mackie C, Neill JC. 2011. Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol. 21:333-343.

McLean SL, Idris NF, Grayson B, Gendle DF, Mackie C, Lesage AS, Pemberton DJ, Neill JC. 2012. PNU-120596, a positive allosteric modulator of alpha7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. J Psychopharmacol. 26:1265-1270.

Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Specking M, Sweeney J, Whittington M, Young LJ. 2012. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature reviews Drug discovery. 11:141-168.

Muir JL, Dunnett SB, Robbins TW, Everitt BJ. 1992. Attentional Functions of the Forebrain Cholinergic Systems - Effects of Intraventricular Hemicholinium, Physostigmine, Basal Forebrain Lesions and Intracortical Grafts on a Multiple-Choice Serial Reaction-Time-Task. Experimental Brain Research. 89:611-622.

Paolone G, Angelakos CC, Meyer PJ, Robinson TE, Sarter M. 2013. Cholinergic control over attention in rats prone to attribute incentive salience to reward cues. J Neurosci. 33:8321-8335.

Parikh V, Ji J, Decker MW, Sarter M. 2010. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci. 30:3518-3530.

Parikh V, Kozak R, Martinez V, Sarter M. 2007. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron. 56:141-154.

Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. 1997. Nicotine activates and desensitizes midbrain dopamine neurons. Nature. 390:401-404.

Poorthuis RB, Bloem B, Schak B, Wester J, de Kock CP, Mansvelder HD. 2013. Layer-specific modulation of the prefrontal cortex by nicotinic acetylcholine receptors. Cerebral Cortex. 23:148-161.

Prendergast MA, Jackson WJ, Terry AV, Jr., Decker MW, Arneric SP, Buccafusco JJ. 1998. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology. 136:50-58.

Prendergast MA, Terry AV, Jr., Buccafusco JJ. 1998. Effects of chronic, low-level organophosphate exposure on delayed recall, discrimination, and spatial learning in monkeys and rats. Neurotoxicol Teratol. 20:115-122.

Quarta D, Naylor CG, Barik J, Fernandes C, Wonnacott S, Stolerman IP. 2009. Drug discrimination and neurochemical studies in alpha7 null mutant mice: tests for the role of nicotinic alpha7 receptors in dopamine release. Psychopharmacology. 203:399-410.

Rezvani AH, Kholdebarin E, Brucato FH, Callahan PM, Lowe DA, Levin ED. 2009. Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry. 33:269-275.

Roberts AC, Robbins TW, Everitt BJ, Jones GH, Sirkia TE, Wilkinson J, Page K. 1990. The effects of excitotoxic lesions of the basal forebrain on the acquisition, retention and serial reversal of visual discriminations in marmosets. Neuroscience. 34:311-329.

Romberg C, Bussey TJ, Saksida LM. 2013. Paying more attention to attention: towards more comprehensive cognitive translation using mouse models of Alzheimer's disease. Brain Res Bull. 92:49-55.
Nicotinic sub-receptor specific modulation of learning and attention

Rombouts JO, Bohte SM, Roelfsema PR. 2015. How attention can create synaptic tags for the learning of working memories in sequential tasks. PLoS computational biology. 11:e1004060.

Sadigh-Eteghad S, Talebi M, Mahmoudi J, Babri S, Shanehbandi D. 2015. Selective activation of alpha7 nicotinic acetylcholine receptor by PHA-543613 improves Abeta25-35-mediated cognitive deficits in mice. Neuroscience. 298:81-93.

Sarter M, Bruno JP, Givens B. 2003. Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? Neurobiol Learn Mem. 80:245-256.

Sarter M, Lustig C, Blakely RD, Koshy Cherian A. 2016. Cholinergic genetics of visual attention: Human and mouse choline transporter capacity variants influence distractibility. J Physiol Paris. 110:10-18.

Schneider JS, Tinker JP, Menzaghi F, Lloyd GK. 2003. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther. 306:401-406.

Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK. 1999. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys. J Pharmacol Exp Ther. 290:731-739.

Smith AC, Frank LM, Wirth S, Yanike M, Hu D, Kubota Y, Graybiel AM, Suzuki WA, Brown EN. 2004. Dynamic analysis of learning in behavioral experiments. J Neurosci. 24:447-461.

St Peters M, Demeter E, Lustig C, Bruno JP, Sarter M. 2011. Enhanced control of attention by stimulating mesolimbic-corticopetal cholinergic circuitry. J Neurosci. 31:9760-9771.

Sun Y, Yang Y, Galvin VC, Yang S, Arnsten AF, Wang M. 2017. Nicotinic alpha4beta2 Cholinergic Receptor Influences on Dorsolateral Prefrontal Cortical Neuronal Firing during a Working Memory Task. J Neurosci. 37:5366-5377.

Tanner JA, Chenoweth MJ, Tyndale RF. 2015. Pharmacogenetics of nicotine and associated smoking behaviors. Curr Top Behav Neurosci. 23:37-86.

Teodoro R, Scheunemann M, Deuther-Conrad W, Wenzel B, Fasoli FM, Gott C, Kranz M, Donat CK, Patt M, Hillmer A, Zheng MQ, Peters D, Steinbach J, Sabri O, Huang Y, Brust P. 2015. A Promising PET Tracer for Imaging of alpha(7) Nicotinic Acetylcholine Receptors in the Brain: Design, Synthesis, and in Vivo Evaluation of a Dibenzothiophene-Based Radioligand. Molecules. 20:18387-18421.

Terry AV, Jr., Plagenhoef M, Callahan PM. 2016. Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. Psychopharmacology. 233:761-771.

Thiele A, Bellgrove MA. 2018. Neuromodulation of Attention. Neuron. 97:769-785.

Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD. 2010. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des. 16:323-343.

Toyohara J, Hashimoto K. 2010. alpha7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. Open Med Chem J. 4:37-56.

van der Meulen JA, Joosten RN, de Bruin JP, Feenstra MG. 2007. Dopamine and noradrenaline efflux in the medial prefrontal cortex during serial reversals and extinction of instrumental goal-directed behavior. Cereb Cortex. 17:1444-1453.

Wadenberg MG, Manetti D, Romanelli MN, Arias HR. 2017. Significance of the nicotinic alpha7 receptor in cognition and antipsychotic-like behavior in the rat. Behav Brain Res. 333:129-134.

Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG. 2011. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav. 99:130-145.

Wallace TL, Bertrand D. 2013. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol. 85:1713-1720.
Nicotinic sub-receptor specific modulation of learning and attention

Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV, Jr., Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA. 2011. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther. 336:242-253.

Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D. 1999. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. The American journal of psychiatry. 156:1931-1937.

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN. 2006. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. J Med Chem. 49:4425-4436.

Wong DF, Kuwabara H, Horti AG, Roberts JM, Nandi A, Casella N, Brasic J, Weerts EM, Kitzmiller K, Phan JA, Gapasin L, Sawa A, Valentine H, Wand G, George N, McDonald M, Kem W, Freedman R, Gjedde A. 2018. PET Brain imaging of alpha7-nAChR with [18F]ASEM: Reproducibility, occupancy, receptor density, and changes in schizophrenia. Int J Neuropsychopharmacol.

Wood C, Kohli S, Malcolm E, Allison C, Shoaib M. 2016. Subtype-selective nicotinic acetylcholine receptor agonists can improve cognitive flexibility in an attentional set shifting task. Neuropharmacology. 105:106-113.

Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AF, Wang M. 2013. Nicotinic alpha7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Natl Acad Sci U S A. 110:12078-12083.

Young JW, Meves JM, Geyer MA. 2013. Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res. 240:119-133.

Zar JH. 2010. Biostatistical Analysis. Upper Saddle River, NJ.: Pearson Prentice-Hall.
Nicotinic sub-receptor specific modulation of learning and attention

Table 1. Overview of results from studies testing the influence of systemic application of selective α4β2 and α7 nAChR's on attention related performance in rodent and nonhuman primate (NHP’s). The details about the fourteen studies using α7* and thirteen α4β2* studies included are outlined in Table S1 and Table S2. The tasks include the sustained attention task (SAT), the choice serial reaction time task (CSRTT), in attentional set shifting and reversal tasks, and in delayed response tasks including the delayed-match-sample task. The symbols denote the result of individual studies reporting either (1) enhanced for at least one dose (“+”), or (2) or only reduced performance (“−”), or which report no effect (“N”).

| nAChRs | Sustained Attention (SAT) | Choice Serial Reaction Time Task (CSRTT) | Attentional Set Shift / Reversal task | Delayed match-to-sample / delayed response tasks |
|--------|---------------------------|-------------------------------------------|--------------------------------------|-----------------------------------------------|
| α4β2*  | NHP: ++                    | ++                                       | ++++ ++ N+                           |                                                |
| Rat:   | ++                       | -+                                       | (+)**                                |                                                |
| α7*    | NHP: +                    | N++ N                                   | ++++                                 |                                                |
| Rat:   | +                        | N++N                                    | +++                                  |                                                |

*The row with α4β2 agonists include the following compounds: ABT-089, ABT-418, ABT-594, S-38232, 5IA-85380, SIB-1508Y, SIB-1553A, 5IA-85380. The row with α7 agonists include the following compounds: A-582941, AR-R17779, GTS-21, PHA-543613, PNU-120596, PNU-282987, RG-3487, SSR-180711. Combined (α4β2 & α7 selective) agonist Varenicline is counted for both drugs.

** This effect was obtained with β2 agonist 5IA-85380.

Table 2. Overview of behavioral results from systemic applied nAChR on the delayed-match-to-sample task with and without distracting events during the delay (DMTS versus dDMTS), and on the sustained attention task with and without delay (SAT, dSAT). “+”: positive effect on performance; “−”: negative effect on performance; “N”: no effect. The details about the included studies are outlined in Table S1 and Table S2.

|                | DMTS | dDMTS | SAT | dSAT |
|----------------|------|-------|-----|------|
| α4β2*          | NHP: | +−N   | +++ | +−   |
| Rat:           |      |       |     |      |
| α7*            | NHP: | ++++2+3++ | +*4 |       |
| Rat:           |      |       |     |      |

* α4β2 agonists included ABT-418 (α4β2 agonist), ABT-594 (α4β2 agonist), S-38232 (α4β2 agonist), SIB-1508Y (α4β4 agonist); α7 agonists included RG-3487 (α7 agonist), A-582941 (α7 agonist), PHA-543613 (α7 agonist)
*1: ABT-089 (α4β2 agonist, young and aged NHP, slow and optimal learner rats),
*2: GTS-21 (α7 agonist, healthy and ketamine impaired monkeys)
*3: PNU-282987 (α7 agonist, cocaine-experienced & naïve),
*4: Varenicline (agonist for α4β2 & α7, ketamine impaired monkeys only)
Figure 1
Figure 2

**A** PHA-543613

- **0.125 mg/kg**
- **0.250 mg/kg**

Monkey H

- Time since injection

- **-log(p)**

- **T1**
- **T2**
- **T3**
- **T4**

Control

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

**B** Monkey K

- **-log(p)**

- **T1**
- **T2**
- **T3**
- **T4**

Control

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

- **α-7 (0.25mg/kg)**

**C** ABT-089

- **0.01 mg/kg**
- **0.02 mg/kg**

Monkey H

- Time since injection

- **-log(p)**

- **T1**
- **T2**
- **T3**
- **T4**

Control

- **α-4/β-2 (0.01mg/kg)**

- **α-4/β-2 (0.02mg/kg)**

- **α-4/β-2 (0.02mg/kg)**

- **α-4/β-2 (0.02mg/kg)**

**D** Monkey K

- **-log(p)**

- **T1**
- **T2**
- **T3**
- **T4**

Control

- **α-4/β-2 (0.01mg/kg)**

- **α-4/β-2 (0.02mg/kg)**

- **α-4/β-2 (0.02mg/kg)**

- **α-4/β-2 (0.02mg/kg)**

n.s.
Figure 3
Figure S2

Start of Performance
30 min. after Injection

Blood Concentration (mg/L)

Time since injection (minute)
Figure S2

Probability of Rewarded Choice

Trials since reversal

0 5 10 15 20 25
0.5
0.6
0.7
0.8
0.9
1

R max

L 50

Figure S2
Figure S3
